COVID-19: Everything you need to know about patient and visitor information.
Viral hepatitis study
The Hepatitis C virus (HCV) Treatment and Prevention (TAP) study is a world first study examining the feasibility of treating with direct acting antiviral drugs using a nurse led model of care in a community based environment for a cohort of HCV-positive people who inject drugs.
The study is being undertaken in collaboration with the Burnet Institute and St Vincent’s Hospital.
The multicentre Australian trial in acute HCV II (ATAHC II) study was an investigator-initiated trial (in collaboration with the Kirby Institute), which investigated the treatment of recently acquired HCV, with the length of treatment (eight to 24 weeks) being governed by the rate of response to pegylated interferon and ribavirin.
The ATAHC Recall Study explored long-term re-infection, liver health and quality of life following acute HCV infection.
The Resolve C Study followed the natural history of a cohort infected with HCV from a single source, healthcare associated outbreak. The Alfred was also involved in international, multicentre studies treating HCV in people co-infected with HIV (PHOTON-2 Study).
